Advertisement

Therapeutische Kontroverse

  • H. Becker
  • K.-H. Bichler
  • ST. H. Flüchter
  • U. W. Tunn
  • G. Ludwig
  • S. D. Fossa
  • H. Rübben
  • U. E. Studer
  • A. Putz
  • K. Bandhauer
  • E. Senn

Zusammenfassung

Beim fortgeschrittenen Prostatakarzinom ist seit den grundlegenden Arbeiten von Huggins u. Hodges (1941) die endokrine Behandlung die Therapie der Wahl. Die Prinzipien dieser Therapie haben sich in den letzten 50 Jahren nicht wesentlich verändert, sie beruhen auf der Senkung des Testosterons. Dieser Testosteronabfall wird erreicht durch Orchiektomie, gegengeschlechtliche Hormone oder neuerdings durch die Applikation von LH-RH Analoga, mit denen eine chemische Kastration erzielt wird. Die Testosteronwerte fallen mit allen 3 Maßnahmen auf etwa 1/10 des Ausgangswertes (Tabelle 1). Die Bedeutung dieser Restandrogene, die überwiegend aus der Nebennierenrinde stammen, ist zum gegenwärtigen Zeitpunkt durch den Versuch einer „kompletten Androgenblockade“ beim fortgeschrittenen Prostatakarzinom wieder aktuell geworden, eine endgültige Beurteilung steht jedoch noch aus.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Alyea EP (1945) Early or late orchiectomy for carcinoma of the prostate. J Urol 53: 143–153Google Scholar
  2. Van Aubel OGJM, Hoekstra WJ, Schroeder FH (1985) Early orchiectomy for patients with stage D 1 prostatic carcinoma. J Urol 134: 292–294PubMedGoogle Scholar
  3. Bartsch W, Horst HJ, Becker H, Nehse G (1977) Sex hormone binding globuline capacity, testosterone, 5-dihydrotestosterone, oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment. Acta Endocrinol (Copenh) 85: 650–664Google Scholar
  4. Byar DP (1973) The Veterans Administration Cooperative Urological Research Group’s Studies of Cancer of the Prostate. Cancer 32: 1126–1130PubMedCrossRefGoogle Scholar
  5. Catalona WJ Prostate cancer. Endocrine therapy, pp 145-171Google Scholar
  6. Emmet JL, Greene LF, Papaution A (1968) Endocrine therapy in carcinoma of the prostate gland: 10-yerar survival studies. J Urol 83: 471–484Google Scholar
  7. Grayhack JT, Kozlowski JM (1980) Endocrine therapy in the management of advanced prostatic cancer: the case of early initiation of treatment. Urol Clin North Am 7: 639–643PubMedGoogle Scholar
  8. Huggins C, Hodges CV (1941) Studies of prostatic cancer: effect of castration, estrogen and androgen injection on serumphosphatase in metastatic carcinoma of the prostate. Cancer Res 1: 293–297Google Scholar
  9. Isaacs JT (1984) The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5: 1–17PubMedCrossRefGoogle Scholar
  10. Klosterhalfen H (1985) Tumoren der Prostata. In: Gross R, Schmidt CG (Hrsg) Klinische Onkologie. Georg Thieme, Stuttgart, S. 32.1–32.34Google Scholar
  11. Klosterhalfen H (1963) Die Behandlungsmethoden des Prostatakarzinoms — Versuch einer medikamentösen Androgenblockade der Nebennierenrinde. Ergeb Chir Orthop 45: 77Google Scholar
  12. Klosterhalfen H, Voigt KD, Tamm J (1965) Die Wirkung der Orchiektomie auf die Ausscheidung von Testosteron, 17-Ketosteroiden, Oestrogenen, Pregnandiol, 17-OH-Corticosteroiden und Gonadotropinen. Urol Int 20: 364PubMedCrossRefGoogle Scholar
  13. Klosterhalfen H, Becker H (1987) 10-Jahres-Ergebnisse einer randomisierten Prospektivstudie beim metastasierten Prostatakarzinom. Akt Urol 18: 234–236CrossRefGoogle Scholar
  14. Kozlowski JM, Ellis WJ, Grayhack JT (1991) Advanced prostatic carcinoma. EarLy versus late endocrine therapy. Urol Clin North Am 18: 15–24PubMedGoogle Scholar
  15. Labrie F, Dupont A, Belanger A, Poyet P, Giguere M, Lacourciere Y, Emond J, Monfelte G, Borsauyi JP (1986) Combined treatment with flutamide and surgical or medical (LHRH agonist) castration in metastatic prostatic cancer. Lancet 49Google Scholar
  16. Lämmel A, Krieg M, Klosterhalfen H, Bressel M, Voigt KD (1986) Bestimmung von Steroidrezeptoren im Prostatakarzinom: Möglichkeiten und Grenzen. Urologe [A] 25: 59–62Google Scholar
  17. Lepor H, Ross A, Walsh PC (1982) The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 128: 335–340PubMedGoogle Scholar
  18. Mackler MA, Liberti JP, Smith MJV, Koontz WW, Prout GR (1972) The effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in patients with carcinoma of the prostate. Invest Urol 9: 423–425PubMedGoogle Scholar
  19. Mukamel E, Nissenkorn I, Servadis C (1980) Early combined hormonal and chemotherapy for metastatic carcinoma of the prostate. Urology 16: 257–260PubMedCrossRefGoogle Scholar
  20. Nesbit RM, Baum WC (1950) Endocrine control of prostatic carcinoma; clinical and statistical survey of 1818 cases. JAMA 143: 1317–1320CrossRefGoogle Scholar
  21. Parker MC, Cook A, Riddle PR, Fryatt I, O’Sullivan J, Shearer RJ (1985) Is delayed treatment justified in carcinoma of the prostate? Br J Urol 57: 724–728PubMedCrossRefGoogle Scholar
  22. Reiner WG, Scott WW, Eggleston JC, Walsh PC (1979) Long-term survival after hormonal therapy for stage D prostatic cancer. J Urol 122: 183–184PubMedGoogle Scholar
  23. Robinson MRG, Thomas BS (1971) Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma. Br Med J 4: 391PubMedCrossRefGoogle Scholar
  24. Shearer RJ, Hendry WF, Sommerville F, Fergusson JD (1973) Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer. Br J Urol 45: 668–677PubMedCrossRefGoogle Scholar
  25. Wenderoth UK, Jacobi GH (1985) Langzeitergebnisse mit dem Gn-RH-Analogon Buserelin (Suprefact) bei der Behandlung des fortgeschrittenen Prostatakarzinoms seit 1981. Akt Urol 16: 58–63CrossRefGoogle Scholar
  26. Williams G (1985) Endocrine treatment of prostatic cancer. J R Soc Med 78: 797–799PubMedGoogle Scholar
  27. Young HH, Kent JR (1968) Plasma testosterone levels in patients with prostatic carcinoma before and after treatment. J Urol 99: 788–792PubMedGoogle Scholar
  28. Zincke H, Utz DC (1984) Observation on surgical management of the carcinoma of the prostate with limited nodal metastases. Urology 24: 137–145PubMedCrossRefGoogle Scholar
  29. Blackard CE, Doe RP, Mellinger GT, Byar DP (1970) Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate. Cancer 26: 249PubMedCrossRefGoogle Scholar
  30. Bouffioux C (1979) Le cancer de 1a prostate. Acta Urol Belg 47: 201Google Scholar
  31. Byar DP (1973) The Veterans Administration Cooperative Urological Research Studies of Cancer of the Prostate. Cancer 32: 1126PubMedCrossRefGoogle Scholar
  32. Byar DP (1977) VACURG Studies on Prostatic Cancer and its Treatment. In: Tannenbaum M (ed) Urologic pathology: the prostate. Lea Febiger, PhiladelphiaGoogle Scholar
  33. Hartley-Asp B (1984) Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3. Prostate 5: 93PubMedCrossRefGoogle Scholar
  34. Harzmann R, Fleischmann R, Flüchter SH, Bichler K-H (1982) Intrahepatic cholestasis as a result of estrogen treatment in prostatic cancer.V. Kongreß der europäischen Vereinigung für Urologie, Wien, 12. bis 15.5.1982Google Scholar
  35. Huggins C, Hodges CV (1941) Studies on prostatic cancer: 1. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293Google Scholar
  36. Huggins C, Clark PJ (1941) Quantitative studies of prostatic secretion. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43: 209CrossRefGoogle Scholar
  37. Huggins C, Sommer JL (1953) Quantitative studies of prostatic secretion. III. Simultaneous measurement of size and secretion of the canine prostate and the interaction of androgenic and estrogenic substances. J Exp Med 97: 663PubMedCrossRefGoogle Scholar
  38. Isaacs JT, Coffey DS (1981) Adaption vs. selection as the mechanism responsible for the relaps of prostatic cancer to androgen ablation as studied in Dunning R-3327-H adenocarcinoma. Cancer Res 41: 5070PubMedGoogle Scholar
  39. Jönsson G, Olsson AM, Luttrop W, Cekan Z, Purvis K, Diczfalusy E (1975) Treatment of prostatic carcinoma with various types of estrogen derivatives. Vitam Horm 33: 351PubMedCrossRefGoogle Scholar
  40. Klosterhalfen H, Becker H (1987) 10-Jahres-Ergebnisse einer randomisierten Prospektivstudie beim metastasierenden Prostatakarzinom. Akt Urol 18: 234–236CrossRefGoogle Scholar
  41. Menon M, Walsh PC (1972) Hormonal therapy for prostatic cancer. In: Murphy GP (ed) Prostatic cancer. PSG, Littleton/MA, p 175Google Scholar
  42. Murphy GP, Beckley S, Brady MF et al. (1983) Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51: 1264PubMedCrossRefGoogle Scholar
  43. Neumann F, El Etreby MF, Habenicht U-F, Radelmaier A, Bohrmacher K (1987) Möglichkeiten des Androgenentzugs und der totalen Blockade. In: Nagel R (Hrsg) Konservative Therapie des Prostatakarzinoms — eine Standortbestimmung. Springer, Berlin Heidelberg New York Tokyo, S 61–86CrossRefGoogle Scholar
  44. Pavone-Macaluso M (1981) EORTC Urological Group (Palermo). Treatment of prostatic carcinoma with hormones and antihormons. In: Altwein JE, Bartsch G, Jacobi GH (Hrsg) Antihormone, Bedeutung in der Urologie. Zuckschwerdt, MünchenGoogle Scholar
  45. Popeliier G (1973) Behandlung des Prostatacarcinoms mit Gestagen. Urologie [A] 12: 134Google Scholar
  46. Schulze H, Senge T (1987) Klassische Methoden des Androgenentzuges in der Therapie des fortgeschrittenen Prostatakarzinoms. In: Nagel R (Hrsg) Konservative Therapie des Prostatakarzinoms — Eine Standortbestimmung. Springer, Berlin Heidelberg New York Tokyo, S 89–98CrossRefGoogle Scholar
  47. Scott WW, Menon M, Walsh PC (1980) Hormonal therapy of prostatic cancer. Cancer 45: 1929PubMedGoogle Scholar
  48. The Leuprolide Study Group (1984) Leuprolide versus diethylstilbestrol for metastatic prostatic cancer. N Engl J Med 311: 1281CrossRefGoogle Scholar
  49. VACURG (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 12: 1012Google Scholar
  50. Arnhold J, Bingold M, Turin UW (1986) Transrektale Prostatasonographie und Regressionsgrading als prognostisches Kriterium des lokalen Tumorresponse beim Prostatakarzinom. Verhandlungsberichte der Deutschen Gesellschaft für Urologie, 37. Kongress, Mainz 1985. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  51. Bingold M, Arnhold J, Tunn UW (1987) Cytostase als primäre oder sekundäre Therapie des fortgeschrittenen Prostatakarzinoms? Verh Dtsch Ges Urol, 38. Tagung, Würzburg. Springer Berlin Heidelberg New York Tokyo, S 128–129Google Scholar
  52. Boccon-Gibod L, Laudat MH, Dugue MA, Steg A (1986) Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate. Eur Urol 12: 400–402PubMedGoogle Scholar
  53. Bracci U (1979) Antiandrogens in the treatment of prostatic cancer. Eur Urol 5: 303–306PubMedGoogle Scholar
  54. Bruchovsky N (1980) Molecular action of androgens and antiandrogens. In: Hammerstein J, Lachnit-Fixson U, Neumann F, Plewig G (eds) Androgenization in women — acne, seborrhoe, androgenetic alopecia and hirsutism. Excerpta Medica, Amsterdam pp 7–20Google Scholar
  55. De Voogt HJ (1985) Second-line endocrine management: anti-androgens an anti-estrogens. EORTC Genitourinary Group monograph 2, part A: therapeutic principles in metastatic prostatic cancer pp 351-357Google Scholar
  56. De Voogt HJ, EORTC-GU-Group (1986) Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer — trials 30761 and 30762. J Urol 135: 303–307PubMedGoogle Scholar
  57. Dorfman RI (1970) Antiandrogenic substances. In: Dorf man RI (ed) Methods in hormone researchGoogle Scholar
  58. Eaton AC, McGuire N (1983) Cyproterone acetat in treatment of postorchidectomy hot flushes. Double-blind cross-over trial. Lancet I: 1336–1337CrossRefGoogle Scholar
  59. Giuliani L, Pescatore D, Gilberti C, Martorana G, Natta G (1980) Treatment of advanced prostatic carcinoma with cyproterone acetate and orchiectomy-5-year-follow-up. Eur Urol 6: 145–148PubMedGoogle Scholar
  60. Habenicht UF, Witthaus E, Neumann F (1986) Antiandrogens and LHRH agonists endocrinology in the initial phase of their use. Akt Urol 17: 10–16CrossRefGoogle Scholar
  61. Isaacs JT (1984) The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5: 1–17PubMedCrossRefGoogle Scholar
  62. Isaacs JT (1985) Mechanisms for resistance of prostatic cancers to androgen ablation therapy. In: Bruchovsky N, Chapdelaine A, Neumann F (eds) Regulation of androgen action. pp 71-76Google Scholar
  63. Jacobi GH (1983) Intramuscular cyproterone acetate treatment for advanced prostatic carcinoma: results of the first multicentric randomized trial. In: Schröder FH (ed) Androgens and antiandrogens. International symposium, June 5th, 1982, Schering Nederland BV, 1983Google Scholar
  64. Jacobi GH, Altwein JE, Kurtz KH, Basting R, Hohenfeller R (1980) Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial. Br J Urol 52: 208PubMedCrossRefGoogle Scholar
  65. Johansson JE, Andersson SO, Beckman KW, Lingardh G, Zador G (1987) Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate. Urology 29: 55–59PubMedCrossRefGoogle Scholar
  66. Karr JP, Murphy GP (1983) Treatment of prostatic carcinoma with combinations of drugs and hormones. In: Bruchovsky N, Chapdelaine A, Neumann F, Brückner R (eds) Regulation of androgen action. Montreal, Berlin, pp 81–86Google Scholar
  67. Klosterhalfen H, Becker H (1987) 10-Jahres-Ergebnisse einer randomisierten Prospektivstudie beim metastasierten Prostatakarzinom. Akt Urol 18: 234–236CrossRefGoogle Scholar
  68. Knuth UA, Hano R, Nieschlag E (1984) Effect of flutamide of cyproterone acetate on pituitary and testicular hormones in normal men. J Clin Endocrinol Metabol (Phil) 59: 963–969CrossRefGoogle Scholar
  69. Labrie F, Dupont A, Belanger A, Lacouriere Y, Raynaud JP, Husson JM, Gareua J, Fazekas ATA, Sandow J, Monfette G, Girard JG, Emond J, Houle JG (1983) New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 4: 579–594PubMedCrossRefGoogle Scholar
  70. Lundgren R (1987) Flutamide as primary treatment for metastatic prostatic cancer. Br J Urol 59: 156–158PubMedCrossRefGoogle Scholar
  71. MacFarlane JR, Tolley DA (1985) Flutamide therapy for advanced prostatic cancer. A phase II study. Br J Urol 57: 172–174PubMedCrossRefGoogle Scholar
  72. Mainwaring WEP (ed) (1977) The mechanism of action of androgens. Monographs on endocrinology, vol 10. Springer, Berlin Heidelberg New YorkGoogle Scholar
  73. Murphy GP, Huben RP, Priore R (1986) Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology XXVIII: 36–40CrossRefGoogle Scholar
  74. Nagel R, Leistenschneider W (1983) Chemotherapie des Prostatakarzinoms. In: Klosterhalfen H (Hrsg) Therapie des fortgeschrittenen Prostatakarzinoms, Med Wiss Buchreihe, Schering AG, S 55–62Google Scholar
  75. Navratil H (1987) Double-blind study of anandron versus placebo in Stage D2 prostate cancer patients receiving buserelin. In: Murphy GP, Khoury S, Küss R, Chatelain C, Denis L (eds) Prostate cancer, part A. Liss, New York, pp 401–410Google Scholar
  76. Neumann F (1983) Pharmacological basis of clinical use of antiandrogens. J Steroid Biochem 19: 391–402PubMedCrossRefGoogle Scholar
  77. Neumann F (1987) Pharmacology and clinical uses of cyproterone acetate. In: Furr BJA, Wakeling AE (eds) Pharmacology and clinical uses of inhibitors of hormone secretion and action. Bailliéfe Tindall, London, pp 132–159Google Scholar
  78. Neumann F, Hümpel M, Senge T, Schenck B, Tunn U (1982) Cyproterone acetate — biochemical and biological basis for treatment of prostatic cancer. In: Jacoby GH, Prostate cancer (book series international perspectives in Hohenfellner RF (eds) urology), Williams & Wilkins, Baltimore, pp 269–302Google Scholar
  79. Neumann F, Etreby MF, Habenicht UT, Radlmeier A, Bormacher K (1987) Möglichkeiten des Androgenentzugs und der totalen Androgenblockade. In: Nagel R (Hrsg) Konservative Therapie des Prostatakarzinoms. Springer, Berlin Heidelberg New York Tokyo, S 61–86CrossRefGoogle Scholar
  80. Pavone-Macaluso M, EORTC-GU-Group (1982) Medroxyprogesterone acetate, diethylstilboestrol and cyproterone acetate in the treatment of prostatic cancer. Interim report of a prospective study of the European Organization for Research on the Treatment of Cancer (EORTC). Genitourinary tract Co-operative Group. Excerpta Med Int Congr Ser 611: 436–444Google Scholar
  81. Pescatore D, Giberti C, Mortorana G, Natta G, Giuliani L (1980) The effect of cyproterone acetate and orchiectomy on metastases from prostatic cancer. Eur Urol 6: 149–153PubMedGoogle Scholar
  82. Prout GR, Irwin RJ, Kliman B, Daly JJ, Maclaughlin R, Griffin PP (1975) Prostatic cancer and Sch-13521. II. Histological alterations and the pituitary gonadal axis. J Urol 113: 834–840Google Scholar
  83. Schroeder FH, Lock TM, Chadha DR, Debruyne FM, Karthaus HF, De-Jong FH, Klijn JG, Matross AW, de-Voogt HJ (1987) Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate. J Urol 137: 912–918PubMedGoogle Scholar
  84. Schulze H, Issacs J, Senge T (1987) Inability of complete androgen blockade to increase survival of patients with advanced prostatic cancer als compared to standard hormonal therapy. J Urol 137: 909–911PubMedGoogle Scholar
  85. Scott WW, Schirmer HK (1966) A new oral progestional steroid effective in treating prostatic cancer. Trans Am Assoc Genitourin Surg 58: 54–60PubMedGoogle Scholar
  86. Servadio C, Mukamel E, Lurie H, Nissenkorn I (1983) Early combined hormonal and chemotherapy for metastatic prostatic carcinoma. Urology XXI: 492–495Google Scholar
  87. Sogani PC, Vagaiwala MR, Whitmore WF (1984) Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 54: 744–750PubMedCrossRefGoogle Scholar
  88. Tremblay D, Dupront A, Meyer BH, Pottier J (1987) The kinetics of antiandrogens in humans. In: Murphy GP et al (eds) Prostate cancer, part A, LissGoogle Scholar
  89. Tunn UW (1987) Antiandrogene in der Therapie des fortgeschrittenen Prostatakarzinoms. In: Nagel R (Hrsg) Konservative Therapie des Prostatakarzinoms — eine Standortbestimmung, Schering-Symposium Berlin 1987, Springer, Berlin Heidelberg New York Tokyo, S 113–121Google Scholar
  90. Tunn UW, Graff J, Senge T (1983 a) Treatment of inoperable prostatic cancer with cyproterone acetate. In: Schröder FH (ed) Androgens and antiandrogens. Schering Nederland BV, pp 149–159Google Scholar
  91. Tunn UW, Senge T, Jacobi GH (1983 b) Klinische Erfahrungen mit Cyproteroneacetat als Monotherapie beim inoperablen Prostatakarzinom. In: Klosterhalfen H (Hrsg) Symposium Prostatakarzinom, Berlin. S 67-76Google Scholar
  92. Tunn UW, Weiglein W, Saborowski J, Senge T (1987) Clinical experience with cyproterone acetate in a randomised and in an open trial. In: Murphy G, Khoury S (eds) Prostate Cancer, A. Liss, New York, pp 365–368Google Scholar
  93. Tunn UW, Radlmeier A, Neumann F (1991) Antiandrogens in cancer treatment. In: Stoll BA (ed) New approaches to hormone modulation in cancer treatment. Karger, Basel (in press)Google Scholar
  94. Varenhorst E, Wallentin L, Risberg B (1981) The effects of orchiectomy, oestrogens and cyproterone acetate on the antithombin-III concentration in carcinoma of the prostate. Urol Res 9: 25–28CrossRefGoogle Scholar
  95. Voigt KD, Bartsch W (1986) Intratussular androgens in benign prostatic hyperplasia and prostatic cancer. J Steroid Biochem 25: 749–757PubMedCrossRefGoogle Scholar
  96. Adam HK, Barker Y (1986) The pharmakokinetics of Zoladex in man after subcutaneous injection and administration in depotform. 14th International Cancer Congress, Budapest, 21.-27. August, posterGoogle Scholar
  97. Altwein JE (1986) Kritische Wertung der Therapie des fortgeschrittenen Prostatakarzinoms. In: Altwein JE, Ludwig G (Hrsg) Neue Wege in der Therapie des fortgeschrittenen Prostatakarzinoms mit LH-RH Agonisten. pmi, Frankfurt, S 1Google Scholar
  98. Beacock CJM (1988) Long-term results of treating advanced prostatic cancer with the LH-RH Analogue Zoladex. Am J Clin Oncol (CCT) 11 [Suppl 2]: 115CrossRefGoogle Scholar
  99. Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E (1978) Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin releasing hormone. Science 202: 631PubMedCrossRefGoogle Scholar
  100. Bischoff Wand German leuprorelin study group (1990) 3,75 und 7,5 mg leuprorelin acetate depot in the treatment of advanced prostatic cancer: preliminary report. J Intern Med Res 18 [Suppl 1]: 103Google Scholar
  101. Borgmann V, Nagel R, Schmidt-Gollwitzer M, Hardt W (1982) Langzeitsuppression der gonadalen Testosteronproduktion durch den LH-RH-Agonisten Buserelinacetat (Hoe 766) beim fortgeschrittenen Prostatakarzinom — eine neue Therapieform? Akt Urol 13: 200CrossRefGoogle Scholar
  102. Clayton RN (1982) Gonadotropon-releasing hormone modulation of its own pituitary receptors: evidence for biphasic regulation. Endocrinology 111: 152PubMedCrossRefGoogle Scholar
  103. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419PubMedCrossRefGoogle Scholar
  104. Debruyne FMJ (1988) Results of a dutch trial with the LHRH agonist Buserelin in patients with metastatic prostatic cancer and results of EORTC Studies in prostatic cancer. Am J Clin Oncol (CCT) 11 [Suppl 1]: 33Google Scholar
  105. Debruyne FMJ, Denis L, Lunglmayr G, Mahler C, Newling DWW, Richards B, Robinson MRG, Smith PhH, Weil EHJ, Whelan P (1988) Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma. J Urol 140: 775PubMedGoogle Scholar
  106. Donabauer HH, Kramer M, Krieg H, Meyer D, Rechenberg W v, Sandow J, Schütz E (1987) Investigations of carcinogenity of the LH-RH analogue buserelin (HOE 766) in rats using the subcutaneous route of administration. Fundam Appl Toxicol 9: 738CrossRefGoogle Scholar
  107. Dupont A, Labrie F, Giguere M, Borsanyi J-P, Lkacourciere Y, Bergeron N, Cusan L, Belanger A, Emond J (1988) Combination therapy with flutamide and [D-Trp6] LHRH ethylamide for stage C prostatic cancer. Eur J Cancer Clin Oncol 24: 659PubMedCrossRefGoogle Scholar
  108. Dutta AS, Furr BJA (1985) Luteinizing hormone releasing hormone analogues. Ann Rep Med Chem 20: 203CrossRefGoogle Scholar
  109. Eickenberg HU (1987) Diskussion zum Vortrag Schröder FH: LHRH-Analoga bei der Behandlung des metastasierten Prostatakarzinoms. In: Nagel R (Hrsg) Konservative Therapie des Prostatakarzinoms. Springer, Berlin Heidelberg New York Tokyo, S 106Google Scholar
  110. Eisenberger MA, O’Dwyer PJ, Friedman MA (1986) Gonadotropin hormone releasinghormone analogues. A new therapeutic approach for prostatic cancer. J Clin Oncol 4: 414PubMedGoogle Scholar
  111. Faure N, Lemay A, Laroche B et al (1983) Preliminary results on the clinical efficacy and safety of androgen inhibition by an LH-RH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoms. Prostate 4: 601PubMedCrossRefGoogle Scholar
  112. Fernandez del Moral P, Hoefakker JW, Debruyne FMJ und die urologische Arbeitsgruppe Süd-Ost Niederlande (1988) Langzeitergebnisse der LHRH-Depot-Therapie (Zoladex) zur Behandlung des metastasierenden Prostatakarzinoms. Verhandlungsber Dtsch Gesellsch Urol, 39. Tagung, 14.-17. Oktober 1987, Stuttgart, Springer, Berlin Heidelberg, New York Tokyo, S 211Google Scholar
  113. Fujino M, Kobayashi S, Obayashi M et al (1972) Structure-activity relationships in the C-terminal part of luteinizing hormone releasing hormone (LH-RH). Biochem Biophys Res Commun 49: 863PubMedCrossRefGoogle Scholar
  114. Furr BJA, Woodborn JR (1988) Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses. J Endocrinol Invest 11: 535PubMedGoogle Scholar
  115. Fontana D, Randone DF, Isaia GC, Dublino M, Colombo M, Giusti M, Bellina M, Valente G, Rolle L, Fasolis G, Porpigli AF (1988) Therapeutic approach to advanced prostatic cancer with the GnRH agonist buserelin: four years of experience. In: Motta M, Serio M (Eds): Hormonal therapy of prostatic diseases: basic and clinical aspects. Proc Int Symp, Milano, Italy (April 6–8, 1987) Medicom, p 234Google Scholar
  116. Garnick MB, Glode LM and the Leuprolide Study Group (1984) Leuprolide versus diethylstilbestfol for metastatic prostate cancer. N Engl J Med 311: 1281CrossRefGoogle Scholar
  117. Glode ML, Smith JA jr. and the Leuprolide Study Group (1987) long-term suppression of luteinizing hormone, follicle-stimulating hormone and testosterone by daily administration of Leuprolide. J Urol 137: 57PubMedGoogle Scholar
  118. Gonzales-Barcena D, Perez-Sanchez PL, Graef A, Gomez AM, Berea H, Comaru-Schally AM, Schally AV (1989) Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-Trp6-LH-RH (Decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma. Prostate 14: 291CrossRefGoogle Scholar
  119. Harris GW (1955) Neural control of the pituitary gland. In: Bayliss LE, Feldberg W, Hodgkin Al (eds): Monographs of the Physiological Society, No. 3. Arnold, LondonGoogle Scholar
  120. Huggins C, Hodges CV (1941) Studies on prostatic cancer I, the effects of castration of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of prostate. Cancer Res 1: 293Google Scholar
  121. Hutchinson FG, Furr BJA (1985) Biodegradable polymers for the sustained release of peptides. Biochem Soc Transact 13: 520Google Scholar
  122. Jacobi GH, Wenderoth UK, WaUenberg H v, Gato M, Hohenfellner R (1988) LH-RH-Analogues for palliation of advanced prostatic carcinoma. A critical review after five years of experience. In: Höffken K (Hrsg) LH-RH-Agonists in Oncology. Springer, Berlin Heidelberg New York, S 72CrossRefGoogle Scholar
  123. Kahan A, Delrien F, Amor B et al (1984) Disease flare induced by D-Trp6-LHRH analogue in patients with metastatic prostatic cancer. Lancet 1: 971PubMedCrossRefGoogle Scholar
  124. Kerle D, Williams G, Ware H, Bloom SR (1984) Failure of long-term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum Br Med J 289: 468CrossRefGoogle Scholar
  125. Koch Y, Baram T, Fridkin M (1977) Resistance to enzymic degradation of LH-RH analogues possessing increased biological activity. Biochem Biophys Res Commun 74: 488PubMedCrossRefGoogle Scholar
  126. Koenig W, Sandow J, Geiger R (1975) Structure-function relationship of LH-RH/FSG-RH. In: Walter R, Meienhofer J (eds) Peptides. Chemistry, structure and biology Proceedings of the fourth American Peptide Symposium 1975. Ann Arbor Science, Ann Arbor, MI, p 883Google Scholar
  127. Koutsilieris M, Faure N, Tolis G, Laroche B, Robert G, Ackman CFD (1986) Objective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either Buserelin or orchiectomy. Urology 3: 221CrossRefGoogle Scholar
  128. Kramer W, Sandow J, Althoff P-H, Balducci M, Jonas D (1988) Die Therapie des fortgeschrittenen Prostatakarzinoms mit Buserelin-Depot. Verhandlungsber Dtsch Gesellsch Urol, 39.Tagung, 14.-17. Oktober 1987, Stuttgart. Springer, Berlin Heidelberg New York Tokyo, S 213Google Scholar
  129. Kreis W, Budman DR, Delli Bovi P, Vinciguerra V (1988) Rapid rise of serum testosterone following discontinuation of long-term treatment of prostate carcinoma with an LHRH-Agonist. Onkologie 11: 292PubMedCrossRefGoogle Scholar
  130. Labile F, Dupont A, Belanger A, Lefebvre FA, Cusan L, Monfette G, Laberge J-G, Edmonds J-P, Raynaud JP, Husson JM, Fazekas ATA (1983) New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen. J Steroid Biochem 19: 999CrossRefGoogle Scholar
  131. Ludwig G (1989) Therapie mit Antiandrogenen. In: Nagel R (Hrsg) Aktuelle Standortbestimmung der konservativen Therapie des Prostatakarzinoms. de Gruyter, Berlin New York, S 117Google Scholar
  132. Ludwig G, Sandow J, Pauthner H (1987) Die Therapie des fortgeschrittenen Prostatakarzinoms mit Buserelin-Implantat. Verhandlungsber Dtsch Ges Urol, 38. Tagung, 23-28 Sept 1986, Würzburg. Springer, Berlin Heidelberg New York Tokyo, S 281Google Scholar
  133. Mahler C, Denis L (1989) Long-term endocrine effects of a luteinizing hormone releasing hormone analogue (LH-RH-A) depot formulation. J Urol 141: 507Google Scholar
  134. Mazzei T, Mini E, Rizzo M, Periti P (1990) Human pharmacokinetic and pharmacodynamic profiles of leuprolin acetate depot in prostatic cancer patients. J Intern Med Res 18 [Suppl 1]:42Google Scholar
  135. Murphy GP, Greco JM, Chin JL, Huben RP, Scott M, de Haan HA (1987) Zoladex (ICI 118630): Clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma. Urology 29: 1985Google Scholar
  136. O’Brien A, Hibberd M (1990) Clinical efficacy and safety of a new leuprolide acetate-depot formulation in patients with advanced prostatic cancer. J Intern Med Res 18 [Suppl 1]: 57Google Scholar
  137. Ogawa Y, Okada H, Heya T et al (1989) Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals. J Pharm Pharmacol 41: 439PubMedCrossRefGoogle Scholar
  138. Papadopoulos I, Kleinschmidt K, Weissbach L (1986) Behandlung des fortgeschrittenen Prostatakarzinoms mit der Depotform eines LHRH Analogous (Decapeptyl). Akt Urol 17: 315CrossRefGoogle Scholar
  139. Parmar H, Lightman SL, Allen L, Phillips RH, Edwards L, Schally AV (1985) Randomised controlled study of orchidectomy vs long-acting D-Trp6-LHRH microcapsules in advanced prostatic carcinoma. Lancet 30: 1201CrossRefGoogle Scholar
  140. Pauthner H (1990) Pharmakokinetik zweier verschiedener Buserelin-Depot-Präparate bei Patienten mit inkurablem Prostatakarzinom. Inaugural-Dissertation. Fakultät für Klinische Medizin Mannheim der Universität HeidelbergGoogle Scholar
  141. Perren TJ, Clayton RN, Blackledge G, Bailey LC, Holder G, Lynch SS, Arkell DG, Cottam J, Farrar G, Young CH (1986) Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (Zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer. Cancer Chemother Pharmacol 18: 39PubMedCrossRefGoogle Scholar
  142. Presant CA, Soloway MS, Klioze SS, Yakabow A, Present SN, Mendez RG, Kennedy PS, Wyres MR, Naessig VL, Todd B, Wiseman CL, Bouzaglou A, Tanenbaum B, Eventov D (1987) Buserelin treatment of advanced prostatic carcinoma. Long-term follow-up of antitumore responses and improved quality of life. Cancer 59: 1713PubMedCrossRefGoogle Scholar
  143. Robinson MRG, Denis L, Mahler C, Walker K, Sitich R, Lunglmayr G (1985) An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections. Europ J Surg Oncol 11: 159Google Scholar
  144. Roger M, Duchier J, Lahlou N, Nahoul K, Schally AV (1985) Treatment of prostatic carcinoma with D-Trp6-LHRH: plasma hormone levels after daily subcutaneous injections and periodic administration of delayed-release preparations. Prostate 7: 271CrossRefGoogle Scholar
  145. Salewski E (1986) Ergebnisse einer Studie an 31 Kliniken zur Therapie des fortgeschrittenen Prostatakarzinoms mit Suprefact. In: Altwein JE, Ludwig G (Hrsg) Neue Wege in der Therapie des fortgeschrittenen Prostatakarzinoms mit LH-RH-Agonisten. PMI, Frankfurt, S 119Google Scholar
  146. Sandow J, Kuhl H, Kraus B (1979) Studies on enzyme stability of LHRH analogues. J Endocrinol 81: 157CrossRefGoogle Scholar
  147. Sandow J, Clayton RN, Kuhl H (1981) Pharmacology of LH-RH and its analogues. In: Crosignani PG, Rubin BL (eds): Endocrinology of human infertility: new aspects. Academic Press, London, p 221Google Scholar
  148. Sandow J, Clayton RN, Kuhl H (1981) Pharmacology of LHRH and its analogues. In: Endocrinology of human infertility. New aspects. Academic Press, London, p 221Google Scholar
  149. Schally AV, Arimura A, Kastin AJ, Matsuo H, Baba Y, Redding TW, Nair RMG, Debeljuk L (1971) Gonadotrophin-releasing hormone: one polypeptide regulated secretion of luteinizing and follicle-stimulating hormones. Science 173: 1036PubMedCrossRefGoogle Scholar
  150. Shimamoto T (1987) Pharmaceutical aspects nasal and depot formulation of leuprolide. J Androl 8: 14Google Scholar
  151. Schröder FH (1987) LHRH-Analoga bei der Behandlung des metastasierenden Prostatakarzinoms. In: Nagel R (Hrsg) Konservative Therapie des Prostatakarzinoms. Springer, Berlin Heidelberg New York Tokyo, S 101CrossRefGoogle Scholar
  152. Schroeder FH, Lock TMTW, Chadha DR, Debruyne FMJ, Karthaus HFM, de Jong FH, Klijn JGM, Matroos AW, de Voogt HJ (1987) Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone azetate. J Urol 137: 912PubMedGoogle Scholar
  153. Schulze H, Senge T (1988) A comparison of the concepts of total and partial androgen blockade in treatment of patients with advanced prostatic cancer. Gynecol Endocrinol 2 [Suppl 1]: 129Google Scholar
  154. Senge TH, Schulze H (1990) Kombinierte Antiandrogen-Therapie. In: Nagel R (Hrsg) Aktuelle Standortbestimmung der konservativen Therapie des Prostatakarzinoms. de Gruyter, Berlin New York, S 141Google Scholar
  155. Seppelt U, Bertermann H, Saerbeck C (1986) Decapeptyl (D-Trp6-LH-RH) zur Therapie von Prostatakarzinomen unter Berücksichtigung eines intramuskulär applizierbaren Depotpräparates. Urologe [A] 25: 298Google Scholar
  156. Smith MA, Perrin MH, Vale WW (1983) Desensitization of cultured pituitary cells to gonadotropon releasing hormone evidence for a post receptor mechanism. Mol Cell Endocrinol 30: 85PubMedCrossRefGoogle Scholar
  157. Smith JA Blode LM Weltlaufer JN Stein BJ Glass AG Max DT Anbar B Jagst CL Murphy GP (1985) Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate. Urology 25: 106PubMedCrossRefGoogle Scholar
  158. Steg A, Chiche R, Boccon-Gibod L, Debre B, Duchiez J, Schally AV (1984) Traitement du cancer de 1a prostate par un agoniste de la LHRH: le D-Trp6-LHRH. Résultats préliminaires Oà propos de 30 observations. Ann Urol 18: 388Google Scholar
  159. Swift AD, Crighton DB (1979) Relative activity, plasma elimination and tissue degredation of synthetic LH-RH and certain of its analogues. J Endocrinol 80: 141PubMedCrossRefGoogle Scholar
  160. de Sy WA, de Wilde G, de Meyer JM, Casselman J, Desmet R, Renders G, Schelfhout W (1988) Long-term experience in the treatment of advanced prostatic cancer with decapeptyl, compared to orchiectomy. Act Urol Belg 56: 581Google Scholar
  161. Tcholakian RK, Delacruz A, Chowdhury M, Steinberger A, Coy DH, Schally AV (1978) Unusual antireproductive properties of the analogue [D-leu6-des-Gly-NH2 10]-luteinizing hormone releasing hormone ethylamide in male rats. Fertil Steril 30, 600Google Scholar
  162. Trachtenberg J (1983) The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue. J Urol 129: 1149PubMedGoogle Scholar
  163. de Voogt HJ, Soloway MS (1985) Prostate cancer. Emphasis on new treatment modalities. Hoechst Medication Up-Date. Series Hormones. Hoechst Aktiengesellschaft.Google Scholar
  164. de Voogt HJ, Robinson MRG, and members of EORTC GU Group and data center, Brussels (1988) EORTC GU Group protocols 30805 and 30843 preliminary results of studies including total androgen blockade. Gynecol Endocrinol 2 [Suppl 1]: 58Google Scholar
  165. Waxman J (1986) Die klinische Anwendung von Buserelin bei Patienten mit fortgeschrittenem Prostatakarzinom: Hormonsekretion während der Langzeitbehandlung mit Buserelin-Nasalspray und erste Erfahrungen mit einem Buserelin-Implantat (Diskussion zu obigem Vortrag) In: Altwein JE, Ludwig G (Hrsg) Neue Wege in der Therapie des fortgeschrittenen Prostatakarzinoms mit LH-RH-Agonisten. pmi, Frankfurt, S 112Google Scholar
  166. Waxman J (1986) Die klinische Anwendung von Buserelin bei Patienten mit fortgeschrittenem Prostatakarzinom: Hormonsekretion während der Langzeitbehandlung mit Buserelin Nasalspray und erste Erfahrungen mit einem Buserelin-Implantat. In: Altwein JE, Ludwig G (Hrsg) Neue Wege in der Therapie des fortgeschrittenen Prostatakarzinoms mit LH-RH-Agonisten. pmi, Frankfurt, S 103Google Scholar
  167. Waxman J (1987) Buserelin and prostatic cancer: pharmacological and endocrino-logical developments. Br J Clin Practice 41 [Suppl 48]: 100Google Scholar
  168. Waxman JH, Wass JAH, Hendry WF, Whitfield HN, Besser GM, Malpas JS, Oliver RTD (1983) Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. Br Med J 286: 1309CrossRefGoogle Scholar
  169. Waxmann JH, Sandow J, Abel P, Farah N, O’Donoghue EPN, Fleming J, Cox J, Sikora K, Williams G (1989) Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancer. Acta Endocrinol (Copenh) 120: 315Google Scholar
  170. Wenderoth UK, Jacobi GH (1985) Langzeitergebnisse mit dem Gn-RH-Analogon Buserelin (Suprefact) bei der Behandlung des fortgeschrittenen Prostatakarzinoms seit 1981. Akt Urol 2: 58CrossRefGoogle Scholar
  171. Wenderoth UK, Jacobi GH (1986) Experience with the GnRH-Analogue Buserelin in the treatment of 122 prostatic cancer patients follows for 4 years. Anticancer Res 6/3A: 378Google Scholar
  172. Wenderoth UK, Spindler HW, Jacobi GH (1986) Fünfwöchige intramuskuläre Applikation des GnRH-Analogs Decapeptyl-Depot beim fortgeschrittenen Prostatakarzinom. Akt Urol 17: 320CrossRefGoogle Scholar
  173. Woijciechowski NJ, Carter CA, Skoutakis VA, Bess DT, Falbe WJ, Mickle TR (1986) Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer. Drug Intell Clin Pharm 20: 746Google Scholar
  174. Williams G, Kerle D, Roe SM, Yeo T, Bloom SR (1985) Results obtained in the treatment of prostate cancer patients with Zoladex. In: EORTC Genitourinary Group Monograph 2, part A: therapeutic principles in metastatic prostatic cancer. Liss, New York, p 287Google Scholar
  175. Andersson L, Berlin T, Boman J et al. (1980) Estramustine versus conventional estrogenic hormones in the initial treatment of highly and moderately differentiated prostate carcinoma, a randomized study. Scand J Urol Nephrol [Suppl] 55: 143–145Google Scholar
  176. Benson RC, Gill GM (1986) Estramustine phosphate compared with diethylstilbestrol. Am J Clin Oncol 9: 341–351PubMedCrossRefGoogle Scholar
  177. Beynon LL, Chisholm GD (1984) The stable state is not an objective response in hormone-escaped carcinoma of prostate. Br J Urol 56: 702–705PubMedCrossRefGoogle Scholar
  178. Chisholm GD, O’Donoghue EPN, Kennedy CL (1977) The treatment of oestrogen-escaped carcinoma of the prostate with estramustine phosphate. Br J Urol 49: 17–720CrossRefGoogle Scholar
  179. de Kernion JN, Murphy GP, Priore R (1988) Comparison of flutamide and emcyt in hormone-refractory metastatic prostatic cancer. Urology 31: 312–317PubMedCrossRefGoogle Scholar
  180. Edsmyr F, Esposti P-L, Andersson L (1980) Estramustine phosphate therapy in poorly differentiated carcinoma of the prostate. Scand J Urol Nephrol 55: 139–142Google Scholar
  181. Edsmyr F, Andersson L, Könyves I (1984) Estramustine phosphate (Estracyt): experimental studies and clinical experience. In: Jacobi GH, Hohenfellner R (eds) Prostate cancer, Williams & Wilkins Baltimore LondonGoogle Scholar
  182. Eisenberger MA, Simon R, O’Dwyer PJ, Wittes RE, Friedman MA (1985) A reevaluatoin of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3: 827–841PubMedGoogle Scholar
  183. Elder JS and Gibbons RP (1985) Results of trials of the USA National Prostatic Cancer Project. In: EORTC Genitourinary Group Monograph 2, part A: therapeutic principles in metastatic prostatic cancer, pp 221-242Google Scholar
  184. Forsgren B, Gustafsson J-Å, Pousette Å, and Högberg B (1979) Binding characteristics of a major protein in rat ventral prostate cytosol that interacts with estramustine, a nitrogen mustard derivative. Cancer Res 39: 5155–5164PubMedGoogle Scholar
  185. Fosså SD, Fosså J, Aakvaag A (1976) Hormone changes in patients with prostatic carcinoma during treatment with estramustine phosphate. J Urol 118: 1013–1018Google Scholar
  186. Fosså SD, Miller A (1975) Treatment of advanced carcinoma of the prostate with estramustine phosphate. J Urol 406-408Google Scholar
  187. Fosså SD, Aaronson NK, Newling D and the members of the EORTC GU Group (1990) Advanced hormone resistant prostatic cancer: preliminary observations on subjective morbidity and palliation. In: Proceedings EAU IXth Congress, Amsterdam, June 13–16Google Scholar
  188. Glashan RW, Robinson MRG (1981) Cardiovascular complications in the treatment of prostatic carcinoma. Br J Urol 53: 624–627PubMedCrossRefGoogle Scholar
  189. Gunnarsson PO, Forshell GP (1984) Clinical pharmacokinetics of estramustine phosphate. Urology 23: 22–27PubMedCrossRefGoogle Scholar
  190. Gunnarsson PO, Andersson S-B, Johansson S-Å, Nilsson T, Plym-Forshell G (1984) Pharmacokinetics of estramustine phosphate (Estracyt® in prostatic cancer patients. Eur J Clin Pharmacol 26: 113–119PubMedCrossRefGoogle Scholar
  191. Hedlund PD, Gustafsson H, Sjögren S (1980) Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. Scand J Urol Nephrol [Suppl] 55: 103–105Google Scholar
  192. Höisaeter PÅ, Bakke A (1984) Clinical experience with Estracyt® as primary treatment. In: Denis L, Murphy GP, Prout GR Schröder F (eds) Controlled clinical trials in urologic oncology. Raven, New York, pp 191–194Google Scholar
  193. Jönsson G, Högberg B, Nilsson T (1977) Treatment of advanced prostatic carcinoma with estramustine phosphate (Estracyt®). Scand J Urol Nephrol 11: 231–238PubMedCrossRefGoogle Scholar
  194. Kanje M, Deinum J, Wallin M, Ekstrøm P, Edstrøm A, Hartley-Asp B (1985) Effect of estramustine phosphate on the assembly of isolated bovine brain microtubules and fast axonal transport in the frog sciatic nerve. Cancer Res 45: 2234–2239PubMedGoogle Scholar
  195. Kühn M, Weissbach L (1990) Primary therapy of metastasized carcinoma with depot Gn RH Analogue (Zoladex) versus estramustine phosphate (EMP; Estracyt). In: Proceedings EAU IXth Congress, Amsterdam, June 13–16Google Scholar
  196. Küss R, Khoury S, Richard F, Fourcade F, Frantz P, Capelle JP (1980) Estramustine phosphate in the treatment of advanced prostatic cancer. Br J Urol 52: 29–33PubMedCrossRefGoogle Scholar
  197. Leistenschneider W, Nagel R (1984) Control of response to estramustine phosphate therapy through cytology and DNA analysis of cell nuclei in prospective study. Urology [Suppl] 6: 23: 81–88Google Scholar
  198. Leistenschneider W, Nagel R (1980) Estracyt therapy of advanced prostatic cancer with special reference to control of therapy with cytology and DNA cytophotometry. Eur Urol 6: 111–115PubMedGoogle Scholar
  199. Lundgren R, Sundin T, Colleen S, Lindstedt E, Wadstrøm L, Carlsson S, Hellsten S, Pompeius R, Holmquist B, Nilsson T, Rubin S, Luttorp W, Jansson H (1986) Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma. Scand J Urol Nephrol 20: 101–105PubMedCrossRefGoogle Scholar
  200. Madajewicz S, Catane R, Mittelman A, Wajsman Z, Murphy GP (1980) Chemotherapy of advanced, hormonally resistant prostatic carcinoma. Oncology 37: 53–56PubMedCrossRefGoogle Scholar
  201. Mareel MM, Storme GA, Dragonetti CH, De Bruyne GK, Hartley-Asp B, Segers JL, Rabacy ML (1988) Antiinvasive activity of estramustine on malignant MO4 mouse cell and on DU-145 human prostate carcinoma cells in vitro. Cancer Res 48: 1842–1849PubMedGoogle Scholar
  202. Murphy GP, Huben RP, Priore R (1986) Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urol 1: 36–42CrossRefGoogle Scholar
  203. Murphy GP, Beckley S, Brady MF et al. (1983) Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51: 1264–1272PubMedCrossRefGoogle Scholar
  204. Newling D, Fosså SD, Tunn U and Kurth KH (1990) The comparison of the effects of high dose estramustine phosphate and Mitomycin C on the time to progression and length of survival of patients with progressive, advanced endocrine independent prostatic cancer: an analysis of EORTC GU Group Study No. 30865. J Steroid Biochem (in press)Google Scholar
  205. Nilsson T, Jönsson G (1976) Primary treatment of prostatic carcinoma with estramustine phosphate: Preliminary report. J Urol 115: 168–169PubMedGoogle Scholar
  206. Pousette Å, Björk P, Carlström, Forsgren B, Högberg B, Gustafsson J-Å (1981) Influence of sex hormones on prostatic secretion protein, a major protein in rat prostate. Cancer Res 41: 688–690PubMedGoogle Scholar
  207. Sandberg AA (1983) Metabolic aspects and actions unique to estracyt. Semin Oncol 10: 3–15PubMedGoogle Scholar
  208. Schmidt J, Gibbons R, Murphy G, Bartolucci A and Investigators of the National Prostatic Cancer Project (NPCP) (1990) Adjuvant treatment of localized prostate cancer following radical surgery and definitive irradiation. Abstract 525, Proc. ASCO 9 135Google Scholar
  209. Slack NH, Murphy GP (1984) Clinical toxicity and long-term results of emcyt therapy for prostate cancer. Urology [Suppl 6] 23: 73–77CrossRefGoogle Scholar
  210. Slack NH, Mittelman A, Rady MF, Murphy GP and Investigators in the National Prostatic Cancer Project (1980) The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancer. Cancer 46: 2393–2402PubMedCrossRefGoogle Scholar
  211. Slack NH, Wajsman Z, Mittelman A, Bruno Salvador, Murphy GP (1979) Relationship of prior hormonal therapy to subsequent estramustine phosphate treatment in advanced prostatic cancer. Urology 14: 549–554PubMedCrossRefGoogle Scholar
  212. Smith PH, Suciu S, Robinson MRG, Richards B, Bastable JRG, Glashan RW, Bouffioux C, Lardennois B, Williams RE, de Pauw M, Sylvester R (1986) A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: Final analysis of a phase III trial of the european organization for research on treatment of cancer. J Urol 136: 619–623PubMedGoogle Scholar
  213. Tannock I, Gospodarowicz, Meakin W, Panzarella T, Stewart L, Rider W (1989) Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7: 590–597PubMedGoogle Scholar
  214. Tew KD, Hartley-Asp B (1984) Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents. Urology [Suppl 6] 23: 28–33CrossRefGoogle Scholar
  215. Tew KD, Stearns ME (1989) Estramustine — A nitrogen mustard/steroid with antimicrotubule activity. Pharmacol Ther 43: 299–319PubMedCrossRefGoogle Scholar
  216. Walzer Y, Oswalt J, Soloway MS (1984) Estramustine phosphate — hormone, chemotherapeutic agent, or both? Urology 24: 53–58PubMedCrossRefGoogle Scholar
  217. Al-Sarraf M (1980) Combination of cytoxan adriamycin and cis-platinum (CAP) in patients with advanced prostatic cancer. Proc AACR ASCO 21: 198Google Scholar
  218. Ansfield FJ, Schroeder J, Curreri AR (1962) Five years clinical experience with 5-fluorouracil. JAMA 181: 295PubMedCrossRefGoogle Scholar
  219. Beckley S, Wajsman Z, Slack N, Mittelman A, Murphy G (1980) The chemotherapy of prostatic carcinoma. Scand J Urol Nephrol [Suppl] 55: 151Google Scholar
  220. Benson RC, Gill GM, Cummings KB (1983) A randomized double blind crossover trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostatic carcinoma. Semin Oncol 10 [Suppl 3]: 43PubMedGoogle Scholar
  221. Benson RC, Gill GM (1986) Estramustine phosphate compared with diethylstilbestrol. Am J Clin Oncol 9: 341PubMedCrossRefGoogle Scholar
  222. Berry WR, Laszlo J, Cox E, Walker N, Paulson D (1979) Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 44: 763PubMedCrossRefGoogle Scholar
  223. Berry J, MacDonald RN (1982) Cisplatin, cyclophosphamide and prednisolone therapy for stage D prostatic cancer. Cancer Treat Rep 66: 1403PubMedGoogle Scholar
  224. Bichler K-H, Flüchter SH (1983) Kriterien in der Progression des Prostatakarzinoms. In: Paul P, Altwein J (Hrsg) Aktuelle Diagnostik und Therapie des Prostatakarzinoms. Erasmusdruck, S 213Google Scholar
  225. Buttyan R, Olsson CA (1984) Androgen receptor assays in advanced prostatic cancer. Urol Clin North Am 11: 311PubMedGoogle Scholar
  226. Chang AY, Bennet JM, Pandya KJ, Asbury R, McCune C (1989) A study of aminoglutethemide and hydrocortisone in patients with advanced and refractory prostate carcinoma. Am J Clin Oncol 12: 358PubMedCrossRefGoogle Scholar
  227. Chlebowski RT, Hestorff R, Sardoff L, Weiner J, Bateman JR (1978) Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer. A randomized trial. Cancer 42: 2546PubMedCrossRefGoogle Scholar
  228. Craig J, Crawford E (1989) Phase II trial of amonafide in advanced prostate cancer: a Southwest Oncology Group Study (meeting abstract). Proc Ann Meet Am Soc Clin Oncol 8: A573Google Scholar
  229. Denis L, Mahler C, Ongena P, Janssen P, De Coster R, Bruynseels J (1990) A phase I/II study with R75251, a novel imdiazole derivate in Ml prostate cancer patients in relapse. Abstracts 98: 187, EAU European Association of Urology, IXth Congress, June 13–16, Amsterdam 1990Google Scholar
  230. De Smedt E, Denis L, Mahler C, Van Oosterom A, Bruyn E (1990) Suramin: A phase I/II study in patients with prostatic cancer in relapse. Abstracts 196: 379, EAU European Association of Urology, IXth Congress, June 13-16, Amsterdam 1990Google Scholar
  231. De Wys WD, Bauer M, Colsky J, Cooper RA, Creeck R, Carbone PP (1977) Comparative trial of adriamycin and 5-fluorouracil in advanced prostatic cancer — progress report. Cancer Treat Rep 61: 325Google Scholar
  232. Eagan RT, Hahn RG, Myers RP (1976) Adriamycin (NSC 127127) versus 5-fluorouracil (NSC 19893) and cyclophosphamid (NSC 26271) in the treatment of metastatic prostate cancer. Cancer Treat Rep 60: 115PubMedGoogle Scholar
  233. Edsmyr F, Adersson L, Könyves J (1982) Estramustine-phosphate: experimental studies and clinical experience. In: Jacobi GH, Hohenfellner R (eds) Prostate cancer. Williams & Wilkins, Baltimore LondonGoogle Scholar
  234. Eisenberger MA (1988) Chemotherapy for prostate carcinoma. NCI Monogr 7: 151PubMedGoogle Scholar
  235. Fossa SD, Aaronson NK, Newling D and the members of the EORTC GU Group (1990) Advanced hormone resistant prostatic cancer: Preliminary observations on subjective morbidity and palliation. Abstracts 2: 4, EAU European Association of Urology, IXth Congress, June 13–16, Amsterdam 1990Google Scholar
  236. Ghosn M, Droz JP, Mahjoubi M, Theodore C, Azab M, Ostronoff M (1989) Phase II trial of ifosfamide (IFO) in hormone-refractory metastatic cancer of the prostate (HRMCP) (meeting abstract). Proc Ann Meet Am Soc Clin Oncol 8: A549Google Scholar
  237. Graf-Dobbdrstein CH, Rübben H, Deutz FJ, Otto U, Block T, Arregui R (1989) Prospektive multizentrische Phase-II-Studie zur Wirksamkeit von Cis platin und Mitomycin in der Therapie des hormonrefraktären Prostatakarzinoms. 4L Kongreß Dtsch Ges Urol 4.-7.10., Freiburg 1989, Abstraktband, S 184Google Scholar
  238. Huggins C, Hodges CV (1941) Studies on prostatic cancer: I. The effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293Google Scholar
  239. Ihde CD, Brunn PA, Cohen MH, Dunnick NR, Eddy JL, Minna JD (1986) Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide. Cancer 45: 1300CrossRefGoogle Scholar
  240. Isaacs JT (1984) The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5: 1PubMedCrossRefGoogle Scholar
  241. Izbicki RM, Amer MH, Al-Sarraf M (1979) Combination of adriamycin and cyclophosphamide in the treatment of metastatic prostatic carcinoma. Cancer Treat Rep 63: 999PubMedGoogle Scholar
  242. Jones WG, Fossa SD, Denis L, Coninx P, Glashan RW, Akdas A, De Pauw M (1983) An EORTC phase II study of vindesine in advanced prostate cancer. Eur J Cancer Clin Oncol 19: 583PubMedCrossRefGoogle Scholar
  243. Jones WG, Bono AV, Verbaeys A, De Pauw M, Sylvester R and members of the EORTC (1986) Can the primary tumour be used as the sole parameter for response in phase II chemotherapy studies in metastatic prostate cancer? An EORTC Genito-urinary Group report. World J Urol 4: 176CrossRefGoogle Scholar
  244. Jones WG, Fossa SD, Bono AV, Croies JJ, Stoter G, De Pauw M, Sylvester R (1986) Mitomycin C in the treatment of metastatic prostate cancer: report of an EORTC phase II study. World J Urol 4: 182CrossRefGoogle Scholar
  245. Kasimis B, Miller JB, Kaneshiro CA et al. (1985) Cyclophosphamide versus 5-fluorouracil, doxorubicin and mitomycin C (FAM) in the treatment of hormone resistant metastatic carcinoma of the prostate: A preliminary report of a randomized trial. J Clin Oncol 3: 385PubMedGoogle Scholar
  246. Keen CW (1980) Half body radiotherapy in the management of metastatic carcinoma of the prostate. J Urol 123: 713PubMedGoogle Scholar
  247. Kennealey GT, Marsh JC, Walsh DA et al. (1978) Treatment of advanced carcinoma of the prostate with estramustine and 5-fluorouracil (FU). Proc Am Assoc Cancer Res, ASCO 19: 394Google Scholar
  248. Kuss R, Khoury S, Richard F et al. (1980) Estramustine phosphate in the treatment of advanced prostatic cancer. Br J Urol 52: 29PubMedCrossRefGoogle Scholar
  249. Kühn M, Weißbach L (1990) Primary therapy of metastasized prostate carcinoma with depot GnRH analogue (Zoladex) versus estramustine phosphate (EMP; Estrazyt), abstracts 132: 254, EAU European Association of Urology, IXth Congress, June 13–16, Amsterdam 1990Google Scholar
  250. Labrie F, Dupont A, Bélanger A, Cusan L, Brochu M, Turina E, Pinault S, Lacourciere Y, Emond J (1989) Anti-hormone treatment for prostate cancer relapsing after treatment with flutamide and castration — addition of aminoglutethimide and low dose hydrocortisone to combination therapy. Br J Urol 63: 634PubMedCrossRefGoogle Scholar
  251. Leistenschneider W, Nagel R (1980) Zytologisches Regressionsgrading und seine prognostische Bedeutung beim konservativ behandelten Prostatakarzinom. Act Urol 11: 236Google Scholar
  252. Linehan WM, LaRocca R, Stein CY, McClellan W, Cooper M, Weiss G, Choyke P, Cassidy J, Ulrich M, Myers CE (1990) Use of suramin in treatment of patients with prostate carcinoma, abstracts 220A: 131, AUA Eighty-Fifth Annual Meeting, May 13–17, New Orleans 1990Google Scholar
  253. Lloyd RE, Jones SE, Salmon SE et al. (1976) Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: a phase II trial. Cancer Treat Rep 60: 77PubMedGoogle Scholar
  254. Logethetis CJ, Eschenbach AC v, Samuels ML, Trindade A, Johnson DE (1982) Doxorubicin, Mitomycin and 5 FU (DMF) in the treatment of hormone resistant stage D prostate cancer: a preliminary report. Cancer Treat Rep 66: 57Google Scholar
  255. Logothetis CJ, Samuels ML, Eschenbach AC v, Trindade A, Ogden S, Grant C, Johnson DE (1983) Doxorubicin, Mitomycin-C, and 5-Fluorouracil (DMF) in the treatment of metastatic hormone refractory-adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol 1: 368PubMedGoogle Scholar
  256. Logothetis CJ, Hossan E, Dexeus FH, Sella A, Amato RJ, Kilbourn RG (1990) Primary combinded chemotherapy and hormonal therapy for the treatment of patients with advanced metastatic adenocarcinoma of the prostate. Abstracts 309A: 481, AUA Eighty-Fifth Annual Meeting, May 13–17, New Orleans 1990Google Scholar
  257. Mahler C, Keuppens F, Nowé P, Van Erps DL (1988) Prospective study of diethylstilbestroldiphosphate in the treatment of prostatic cancer in relapse. Urol Int 43: 47CrossRefGoogle Scholar
  258. Merrin C, Etra W, Wajsman Z, Baumgartner G, Murphy G (1976) Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin. J Urol 115: 86PubMedGoogle Scholar
  259. Merrin CE (1979) Treatment of genitourinary tumors with cisdichlorodiamineplatinum (II): experience in 250 patients. Cancer Treat Rep 63: 1579PubMedGoogle Scholar
  260. Mittleman A, Shukla SK, Murphy GP (1976) Extended therapy of stage D carcinoma of the prostate with oral estramustine phosphate. J Urol 115: 409Google Scholar
  261. Moore GE, B ross ID J, Ausman R et al. (1968) Effects of 5-fluorouracil (NSC-19893) in patients with cancer. Eastern Clinical Drug Evaluation Program. Cancer Chemother Rep 52: 641Google Scholar
  262. Moore MR, Trôner MB, Desimone P et al. (1986) Phase II evaluation of weekly cisplatin in metastatic hormone resistant prostate cancer: a Southeastern Cancer Study Group trial. Cancer Treat Rep 70: 541PubMedGoogle Scholar
  263. Murphy G (1978) Management of advanced cancer of the prostate. In: Skinner DF, De Kernion JB (eds) Genitourinary cancer. Saunders, PhiladelphiaGoogle Scholar
  264. Murphy GP, Slack NH and participants in the National Prostatic Cancer Project (1984) Current status of the National Prostatic Cancer Project Treatment Protocols. In: Denis L, Murphy GP, Prout GR, Schröder F (eds) Controlled clinical trial in urologic oncology. Raven, New York, p 13Google Scholar
  265. Muss HB, Howard V, Richards F, White DR, Jackson DV, Cooper MR, Stuart JJ, Resnick MI, Brodkin R, Spurr CL (1981) Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-flubrouracil in advanced prostatic cancer — a randomized trial. Cancer 47: 1949PubMedCrossRefGoogle Scholar
  266. O’Bryan RM, Luce JK, Talley RW et al. (1973) Phase II evaluation of adriamycin in human neoplasia. Cancer 32: 1PubMedCrossRefGoogle Scholar
  267. O’Bryan RM, Baker LH, Gottlieb JF et al. (1977) Dose-response evaluation of adriamycin in human neoplasia. Cancer 39: 1940PubMedCrossRefGoogle Scholar
  268. Paulson DF, Berry WR, Cox EB et al. (1979) Treatment of metastatic endocrineunresponsive carcinoma of the prostate gland with multiagent chemotherapy: indicators of response to therapy. JNCI 63: 615PubMedGoogle Scholar
  269. Qazi R, Khandekar J (1983) Phase II study of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 6: 203Google Scholar
  270. Rübben H (1986) Chemotherapie beim Prostatakarzinom. Onkol Forum Chemother (Schwerpunkt Prostatakarzinome) 2: 11Google Scholar
  271. Rübben H, Altwein JE (1987) Das fortgeschrittene Prostatakarzinom — Ein therapeutisches Dilemma? Urologe [A] 26: 7Google Scholar
  272. Rossof AM, Talley RW, Stephens RL, Thigpen T, Samson MK, Groppe C, Eyre HJ, Fisher R (1979) Phase II evaluation of cis-dichlorodiamineplatinum (II) in advanced malignancies of the genitourinary and gynecologic organs, Southwest Oncology Groups Study. Cancer Treat Rep 63: 1557PubMedGoogle Scholar
  273. Scott WW, Gibbons RP, Johnson DE, Prout GR, Schmidt JD, Saroff J, Murphy GP (1976) The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate. J Urol 116: 211PubMedGoogle Scholar
  274. Seppelt U, Sprenger E (1980) Zellkern-DNS-Analysen durch Einzelzell-Fluoreszenz-Zytophotometrie an Prostatakarzinomen vor und während der Therapie. Verh Dtsch Ges Urol 32: 68Google Scholar
  275. Smalley RV, Bartolucci AA, Hemstreet G, Hester M (1981) A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and or 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. J Urol 125: 191PubMedGoogle Scholar
  276. Soloway MS, Shippel RM, Ikard M (1979) Cyclophosphamide, doxorubicin hydrochloride, and 5-fluorouracil in advanced carcinoma of the prostate. J Urol 122: 637PubMedGoogle Scholar
  277. Soloway MS, De Kernion JB, Gibbons RP, Johnson DE, Leoning SA, Pontes JE et al. (1981) Comparison of estramustine phosphate and vincristin alone or in combination for patients with advanced hormone refractory, previously irradiated carcinoma of the prostate. J Urol 125: 664PubMedGoogle Scholar
  278. Soloway MS, Beckley S, Brady MF et al. (1983) A comparison of estramustine phosphate, versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had extensive irradiation to the pelvis or lumbosacral area. J Urol 129: 56PubMedGoogle Scholar
  279. Schmidt JD, Gibbons RP, Johnson DE, Prout GR, Scott WW, Murphy GP (1976) Chemotherapy of advanced prostatic cancer. Urology 6: 602CrossRefGoogle Scholar
  280. Schmidt JD, Scott WW, Gibbons RP, Johnson DE, Prout GR, Loening SA et al. (1979) Comparison of procarbazine, imidazole-carboxamide and cyclophosphamide in relapsing patients with advanced carcinoma of prostate. J Urol 121: 185PubMedGoogle Scholar
  281. Straus MJ, Farmelee J, Olsson C, De Vere White R (1978) Cytoxan, adriamycin and methotrexate (CAM) therapy of stage D prostate cancer. Proc Am Assoc Cancer Res, Am Soc Clin Oncol 19: 314Google Scholar
  282. Torti F, Aston D, Lum BL et al. (1983) Weekly doxorubicin in endocrine refractory carcinoma of the prostate. J Clin Oncol 1: 477PubMedGoogle Scholar
  283. Torti FM, Shortliffe L, Carter SK et al. (1985) A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma. Cancer 56: 2580PubMedCrossRefGoogle Scholar
  284. Trachtenberg J, Walsh PC (1982) Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. J Urol 127: 466PubMedGoogle Scholar
  285. Tubiana M, Malaise E (1976) Comparison of cell proliferation kinetics in human and experimental tumors: response to irradiation. Cancer Treat Rep 60: 1887PubMedGoogle Scholar
  286. Yagoda A (1979) Phase II trials with cis-diamine-dichloroplatinum (II) in the treatment of urothelial tumors. Cancer Treat Rep 63: 1565PubMedGoogle Scholar
  287. Yagoda A, Watson RC, Natale RB et al. (1979) A critical analysis of response criteria in patients with prostatic cancer treated with cis-diaminedichloride platinum II. Cancer 44: 1553PubMedCrossRefGoogle Scholar
  288. Beckley S, Wajsman LZ, Slack NH, Murphy GP (1981) Chemotherapy in metastatic, hormone refractory prostatic cancer using chlorambucil in combination with prednisolone versus conjugate, prednimustine (Leo 1031). Urology XVII 5: 446–448CrossRefGoogle Scholar
  289. Beckley S, Wajsman Z, Maeso E, Pontes E, Murphy G (1981) Estramustine phosphate with multiple cytotoxic agents in treatment of advanced prostatic cancer. Urology XVIII 6: 592–595CrossRefGoogle Scholar
  290. Bracci U (1979) Antiandrogens in the treatment of prostatic cancer. Eur Urol 5: 303PubMedGoogle Scholar
  291. Brendler H, Prout GR Jr (1962) A cooperative group study of prostatic cancer? stilbestrol versus placebo in advanced progressive disease. Cancer Chemo Rep 16: 323–327Google Scholar
  292. Bruchovsky N, Brown EM, Coppin CM, Goldenberg SL, Le Riche JC, Murray NC, Rennie PS (1987) The endocrinology and treatment of prostate tumor progression. In: Progress in clinical and biological research. Liss, New York (Current concepts and approaches to the study of prostate cancer), pp 347–387Google Scholar
  293. Byar DP (1973) The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate. Cancer 32: 1126–1130PubMedCrossRefGoogle Scholar
  294. Citrin DL, Hogan TF (1982) A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer. Cancer 50: 201–206PubMedCrossRefGoogle Scholar
  295. Citrin DL, Dies MS, Wallemark CB (1985) A phase II study of high-dose estrogens (diethylstilbestrol diphosphate) in prostate cancer. Cancer 56: 457–460PubMedCrossRefGoogle Scholar
  296. Cockburn AG (1983) Carcinoma of the prostate: delayed endocrine therapy is best. Semin Urol 1: 280–287PubMedGoogle Scholar
  297. Coffey DS, Isaacs JT (1981) Prostate tumor biology and cell kinetics — theory. Urology [Suppl] 17: 40–53Google Scholar
  298. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419–424PubMedCrossRefGoogle Scholar
  299. deKernion JB, Lindner A (1984) Chemotherapy of hormonally unresponsive prostatic carcinoma. Urol Clin North Am 2: 319–326Google Scholar
  300. de Voogt HJ, Klein JG, Studer U, Sylvester R, de Pauw M and members of the EORTC GU-group (1990) The use of LHRH-agonist Buserelin, combined with the anti-androgen cyproterone-acetate versus orchidectomy in the treatment of advanced prostatic cancer: preliminary results of EORTC-trial 30843. Eur Urol 18 (S1): 98Google Scholar
  301. Drago JR (1984) Chemotherapy in prostatic cancer urologic oncology. Nijhoff, Boston, pp 51–77Google Scholar
  302. Eisenberger MA Simon R O’Dwyer PJ (1985) A réévaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3: 827–841PubMedGoogle Scholar
  303. Eisenkraft S, Huben RP, Pontes JE (1984) Orchiectomy and chemotherapy with estramustine, cis-platinum, cyclophosphamide, and 5-fluorouracil in newly diagnosed prostate cancer with bone metastases. Urology XXIII: 51–53CrossRefGoogle Scholar
  304. Fauré N, Lemay A, Larode B et al. (1983) Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma. Prostate 4: 601–624PubMedCrossRefGoogle Scholar
  305. Fourcade RO, Cariou G, Coloby P, Colombel P, Coulange C, Grise P, Mangin P, Soret JY, Poterre M (1990) Total androgen blockade in advanced prostatic carcinoma: interim report of a double blind study using Zoladex and Flutamide. J Urol 143: 220AGoogle Scholar
  306. Fowler JE, Whitmore Jr WF (1982) Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer. Cancer 49: 1373–1377PubMedCrossRefGoogle Scholar
  307. Fox M, Hammonds JC (1980) Palliative effect of cyproterone acetate in carcinoma of the prostate with widespread metastatic bone disease. Br J Urol 52: 402PubMedCrossRefGoogle Scholar
  308. Fukushima DK (1978) Effect of flutamide on cortisol meta bolism. J Clin Endocrinol Metab 47: 488CrossRefGoogle Scholar
  309. Garnick MB (1986) Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Urology XXVII [Suppl 1]: 21–26CrossRefGoogle Scholar
  310. Gibbons RP, Beckley S, Brady MF (1983) The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate. J Surg Oncol 23: 133–142PubMedCrossRefGoogle Scholar
  311. Grossman HB (1986) Hormonal therapy of prostatic carcinoma: is there a rationale for delayed treatment? Urology XXVII: 199–204CrossRefGoogle Scholar
  312. Herr HW (1982) Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexyl-nitrosourea in the treatment of metastatic prostatic cancer. J Urol 127: 462–465PubMedGoogle Scholar
  313. Holdaway I, Altwein JE, Klippel KF, Lunglmayr G, Tyrrell CJ, Varenhorst E (1990) A multicentre randomised trial comparing the LHRH agonist „Zoladex“ with „Zoladex“ in combination with flutamide in the treatment of advanced prostate cancer. J Urol 143: 220AGoogle Scholar
  314. Hüben RP, Murphy GP and the investigators of the National Prostatic Cancer Project (1988) A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate. Cancer 62: 1881–1887PubMedCrossRefGoogle Scholar
  315. Isaacs JT (1984) The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5: 1–17PubMedCrossRefGoogle Scholar
  316. Isaacs JT, Coffey DS (1981) Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 41: 5070PubMedGoogle Scholar
  317. Klign JGM, de Voogt HJ, Schröder FH, de Jong FH (1985) Combined treatment with buserelin and cyproterone acetate in metastatic prostatic carcinoma. Lancet 2: 493PubMedCrossRefGoogle Scholar
  318. The Leuprolide Study Group (1984) Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311: 1281–1286CrossRefGoogle Scholar
  319. Logothetis CJ, Samuels ML, Eschenbach AC v (1983) Doxorubicin, Mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol 1:368PubMedGoogle Scholar
  320. Lund F, Rasmussen F (1988) Flutamide versus stilboestrol in the management of advanced prostatic cancer. Br J Urol 61: 140–142PubMedCrossRefGoogle Scholar
  321. Merrin CE (1980) Treatment of previously untreated (by hormonal manipulation) stage D adenocarcinoma of prostate with combined orchiectomy, estrogen, and Cis diaminedichloroplatinum. Urology XV: 123–125CrossRefGoogle Scholar
  322. Mukamel E, Nissenkorn I, Servadio C (1980) Early combined hormonal and chemotherapy for metastatic carcinoma of prostate. Urology XVI: 257–260CrossRefGoogle Scholar
  323. Murphy GP, Beckley S, Brady M (1983) Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51: 1264–1272PubMedCrossRefGoogle Scholar
  324. Murphy GP, Hüben RP, Priore R (1986) Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology XXVIII: 36–40CrossRefGoogle Scholar
  325. Muss HB, Howard V, Richards F, White DR, Jackson DV, Cooper MR, Stuart JJ, Resnick MI, Brodkin R, Spurr CL (1981) Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer. Cancer 47: 1949–1953PubMedCrossRefGoogle Scholar
  326. Nesbit RM, Baum WC (1950) Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. JAMA 143: 1317–1320CrossRefGoogle Scholar
  327. Parker MC, Cook A, Riddle PR (1985) Is delayed treatment justified in carcinoma of the prostate? Br J Urol 57: 724–728PubMedCrossRefGoogle Scholar
  328. Paulson DF (1978) The role of endocrine therapy in the management of prostatic cancer. In: Skinner DG, deKernion JB (eds) Genitourinary cancer. Saunders, Philadelphia, p 388Google Scholar
  329. Paulson DF (1985) Management of metastatic prostatic cancer. Urology [Suppl] 25: 49–52PubMedCrossRefGoogle Scholar
  330. Paulson DF, Walker RA, Berry WR, Cox EB, Hinshaw W (1981) Vincristine, bleomycin, methotrexate, 5-fluorouracil, and prednisone in metastatic, hormonally unresponsive prostatic adenocarcinoma. Urology XVII: 443–445CrossRefGoogle Scholar
  331. Resnick MI, Grayhack JT (1975) Treatment of stage IV carcinoma of the prostate. Urol Clin North Am 2: 141–161PubMedGoogle Scholar
  332. Robinson MRG, Hetherington J (1986) The EORTC studies: is there an optimal endocrine management for M1 prostatic cancer? World J Urol 4. 171–175CrossRefGoogle Scholar
  333. Rost A (1981) Cyproterone acetate, testosterone, LH, FSH, and prolactin levels in plasma after intramuscular application of cyproterone acetate in patients with prostatic cancer. Prostate 2: 315PubMedCrossRefGoogle Scholar
  334. Saiers JH, Tramum BL, Stephens R (1985) Treatment of stage D II adenocarcinoma of the prostate with doxorubicin, mitomycin C and 5-fluorouracil; a South-West Oncology Group study. Proc Am Soc Clin Oncol 4: 108CrossRefGoogle Scholar
  335. Sanford EJ, Drago JR, Rohner TJ (1976) Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma. J Urol 115: 170PubMedGoogle Scholar
  336. Scher HI, Sternberg CN (1985) Chemotherapy of urologic malignancies. Semin Urology III: 239–280Google Scholar
  337. Schröder FH, Lock TMTW, Chadha DR, Debruyne FMJ, Karthaus HFM, de Jong FH, Klijn JGM, Matroos AW, de Voogt HJ (1987) Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate. J Urol 137: 912–918Google Scholar
  338. Scott WW, Menon M, Walsh PC (1980) Hormonal therapy of prostatic cancer. Cancer 45: 1929–1936PubMedGoogle Scholar
  339. Servadio C, Mukamel E, Lurie H, Nissenkorn I (1983) Early combined hormonal and chemotherapy for metastatic prostatic carcinoma. Urology XXI: 493–495CrossRefGoogle Scholar
  340. Sogani PC, Whitmore WF (1979) Experience with flutamide in previously untreated patients with advanced prostatic cancer. J Urol 122: 640PubMedGoogle Scholar
  341. Torti FM, Flam M, Lum BL (1985) Weekly adriamycin and methotrexate in endocrine unresponsive carcinoma of the prostate. Proc Am Soc Clin Oncol 4: 103Google Scholar
  342. Tveter KJ, Otnes B, Hannestad R (1978) Treatment of prostatic carcinoma with cyproterone acetate. Scand J Urol Nephrol 12: 115PubMedCrossRefGoogle Scholar
  343. The Veterans Administration Cooperative Urological Research Group (1967) Carcinoma of the prostate: treatment comparions. J Urol 98: 516–522Google Scholar
  344. Walsh PC (1975) Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 2: 125–140PubMedGoogle Scholar
  345. Zadra J, Bruce AW, Trachtenberg J (1986) Total androgen ablation therapy in the treatment of advanced prostate cancer. J Urol 135: 201AGoogle Scholar
  346. Alsheik HI, Guinan PD, Abiin RJ, Nourkayhan SH, Bruns RB, Sadoughi N et al. (1977) The effect of transurethral resection of the prostate on lymphocyte response in patients with prostatic cancer. J Urol 118: 1022PubMedGoogle Scholar
  347. Bandhauer K (1982) Has transurethral resection a place in prostate cancer management? In: Jacobi GH, Hohenfellner R (eds) Prostate cancer 3. Williams & Wilkins, Baltimore London, pp 245–251Google Scholar
  348. Bandhauer K (1975) The possible role of transurethral resection in the dissemination of prostatic cancer. Eur Urol 1: 272PubMedGoogle Scholar
  349. Bartsch G, Hohlbrugger G, Mikuz G, Diethe O, Marberger H (1983) Die transurethrale Elektroresektion beim Prostatakarzinom. Aktuelle Diagnostik und Therapie des Prostatakarzinoms. 2. Seminar für urologische Onkologie des Berufsverbandes Deutscher Urologen e.V. 24.-26.9.1982, Neu-Isenburg 204, 1983Google Scholar
  350. Egle N, Spieler P, Bandhauer K, Gloor F (1976) Die Bedeutung zytologischer Untersuchungen für die primäre Diagnostik und den klinischen Verlauf des Prostatakarzinoms. Akt Urol 7: 355–361Google Scholar
  351. Epstein JI, Oesterling JE, Walsh CP (1988) The volume and anatomical location of residual tumor in radical prostatectomy specimens removed for stage Al prostate cancer. J Urol 139: 975–979PubMedGoogle Scholar
  352. Fowler JE, Fisher HAG, Kaiser DL, Withmore WF (1984) Relationship of pretreatment transurethral resection of the prostate to survival without distant metastases in patients treated with 1251-implantation for localized prostatic cancer. Cancer 53: 1857–1863PubMedCrossRefGoogle Scholar
  353. Hanks GE (1985) Optimizing the radiation treatment and outcome of prostate cancer. Int J Radiat Oncol Biol Phys 11: 1235–1245PubMedCrossRefGoogle Scholar
  354. Hanks EG, Leibel S, Kramer S (1983) The dissemination of cancer by transurethral resection of locally advanced prostate cancer. J Urol 129: 309–311PubMedGoogle Scholar
  355. Jewett HJ (1976) Radical perineal prostatectomy for prostatic cancer. In Marberger H, Hascheck H, Schirmer HKA, Colston JAC, Witkin E (eds) Progress in clinical and biological research, vol 6. Liss, New York, pp 205–218Google Scholar
  356. Kang Fan, Chung-Fu Peng (1983) Predicting the probability of bone metastasis through histological grading of prostate autopsy cases with antemortem transurethral resection specimen. J Urol 130: 708–711Google Scholar
  357. Küss R, Khoury S (1978) Letter to the editor. J Urol 120: 388PubMedGoogle Scholar
  358. McGowan DG (1980) The adverse influence of prior transurethral resection on prognosis in carcinoma of the prostate treated by radiation therapy. Int J Radiat Oncol Biol Phys 6: 1121–1126.PubMedCrossRefGoogle Scholar
  359. Meacham RB, Scardino PT, Hoffman GS, Easley JD, Wilbanks JH, Carlton CE (1989) The risk of distant metastases after transurethral resection of the prostate versus needle biopsy in patients with localized prostate cancer. J Urol 142: 320–325PubMedGoogle Scholar
  360. Sandier MH, Hanks GE (1988) Analysis of the possibility that transurethral resection promotes metastasis in prostate cancer. Cancer 62: 2622–2627CrossRefGoogle Scholar
  361. Scardino PT (1985) The adverse effect of TUR in carcinoma of the prostate. Abstr Proc Urol Soc Austr, Br J Urol 31: 89Google Scholar
  362. Toggenburg H, Bandhauer K, Spieler P (1984) Wert der Zytodiagnostik für die Verlaufskontrolle des Prostatakarzinoms. In: Helpap B, Senge T, Vahlensieck W (Hrsg) Die Prostata/Prostatakarzinom, Bd 2.2. Prostata-Workshop in Frankfurt/M. 20.-21.1.1984. PMI, Frankfurt, S 325–330Google Scholar
  363. Vicente J, Chéchile G, Algaba F (1989) The role of repeat transurethral resection in stage Al carcinoma of the prostate. Eur Urol 16: 325–327PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • H. Becker
  • K.-H. Bichler
  • ST. H. Flüchter
  • U. W. Tunn
  • G. Ludwig
  • S. D. Fossa
  • H. Rübben
  • U. E. Studer
  • A. Putz
  • K. Bandhauer
  • E. Senn

There are no affiliations available

Personalised recommendations